LENZ Therapeutics, Inc. (Nasdaq: LENZ) — Point-in-Time Research (as of 2026-11-01)

Background

LENZ Therapeutics is a San Diego, California–headquartered commercial pharmaceutical company focused on developing and commercializing ophthalmic therapies for presbyopia (age-related loss of near vision) in the United States. Its flagship product is VIZZ® (aceclidine ophthalmic solution) 1.44%, described as the first and only FDA-approved aceclidine-based eye drop for presbyopia. The company was formerly Presbyopia Therapies, Inc. [14], [18], [20]. As of late October 2026, it carried a market capitalization of approximately $95.83 million, with a stock price near $3.05 and roughly 31.4 million shares outstanding [13], [14], [16], [17], [18].

Recent Catalysts (roughly July–October 2026)